Personalis (NASDAQ:PSNL) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Posted by Geri Gentry on Aug 6th, 2026

Personalis (NASDAQ:PSNL – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04), FiscalAI reports. The business had revenue of $22.36 million for the quarter, compared to analysts’ expectations of $16.69 million. Personalis had a negative return on equity of 46.78% and a negative net margin of 153.84%.

Personalis Trading Down 1.2%

Shares of Personalis stock traded down $0.16 during trading hours on Thursday, hitting $13.36. 614,847 shares of the company were exchanged, compared to its average volume of 2,549,905. The business has a 50-day moving average of $12.29 and a 200-day moving average of $9.28. Personalis has a 1 year low of $4.28 and a 1 year high of $16.39. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -12.27 and a beta of 2.27.

Insider Buying and Selling at Personalis

In other news, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.15, for a total value of $1,315,000.00. Following the sale, the chief executive officer owned 235,986 shares of the company’s stock, valued at $3,103,215.90. The trade was a 29.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the transaction, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,620,618.94. This trade represents a 20.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 435,032 shares of company stock worth $5,599,929 over the last three months. 4.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Personalis

A number of institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc purchased a new position in shares of Personalis during the 2nd quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Personalis by 184.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock valued at $44,000 after buying an additional 3,592 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after buying an additional 5,177 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Personalis in the fourth quarter valued at approximately $82,000. Finally, DRW Securities LLC acquired a new position in Personalis during the fourth quarter worth $83,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Analyst Ratings Changes

PSNL has been the subject of a number of recent research reports. Lake Street Capital cut shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target for the company. in a research note on Monday, July 20th. Needham & Company LLC lowered shares of Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. BTIG Research upped their target price on shares of Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a report on Monday, July 20th. Morgan Stanley increased their target price on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Finally, Zacks Research lowered Personalis from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 21st. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $14.25.

View Our Latest Analysis on PSNL

About Personalis

(Get Free Report)

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.